haloperidol and 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline

haloperidol has been researched along with 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schmidt, WJ; Zadow, B1
Bittigau, P; Bosch, F; Dikranian, K; Ikonomidou, C; Miksa, M; Olney, JW; Stefovska, V; Tenkova, TI; Turski, L; Vöckler, J1

Other Studies

2 other study(ies) available for haloperidol and 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline

ArticleYear
The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
    Naunyn-Schmiedeberg's archives of pharmacology, 1994, Volume: 349, Issue:1

    Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Drug Interactions; Ergolines; Haloperidol; Levodopa; Male; Pilot Projects; Quinoxalines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA

1994
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
    Science (New York, N.Y.), 1999, Jan-01, Volume: 283, Issue:5398

    Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Fetus; Haloperidol; Immunohistochemistry; In Situ Nick-End Labeling; Microscopy, Electron; Muscarinic Antagonists; Nerve Degeneration; Neurons; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Scopolamine

1999